Compare Amgen, Inc. (AMGN) vs The Coca-Cola Co K (KO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs The Coca-Cola Co K — how do they compare? Amgen, Inc. trades at $366.75 (market cap $196.12B), while The Coca-Cola Co K trades at $84.1 (market cap $359.21B). The key difference: The Coca-Cola Co K is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | KO | |
|---|---|---|
Market Cap | $196.12B | $359.21B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $84.14 |
52-Week Low | $271.18 | $65.67 |
Enterprise Value | $241.41B | $389.28B |
Dividend Yield | 2.77% | 2.54% |
Volume | — | 14,630,257 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Coca-Cola (KO) trades at $83.49, up 1.04% on the day, with a bullish technical signal from moving averages and strong support at $82. The company has beaten EPS estimates for the last three quarters, with Q2 2026 expected at $0.92. Revenue grew to $47.94 billion in 2025, with a robust net income margin of 27.8%. Recent news highlights institutional buying and stable demand trends, while the FIFA World Cup 2026 Trophy Tour underscores brand strength.
The outlook remains positive with a consensus price target of $89.00, implying ~6.6% upside. Strengths include consistent earnings beats, high profitability, and dividend reliability. Risks involve regional demand divergence in Asia, high debt levels, and valuation multiples above industry averages. Analyst sentiment is bullish (60% Buy), supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
